Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Indian Journal of Pediatrics
Published in: Indian Journal of Pediatrics 4/2018

01-04-2018 | Original Article

Effects of Growth Hormone Treatment on Lipid Profiles

Authors: Toshihide Kubo, Mahoko Furujo, Kyohei Takahashi, Yuki Hyodo, Hiroki Tsuchiya, Mariko Hattori, Shoko Fujinaga, Kenji Urayama

Published in: Indian Journal of Pediatrics | Issue 4/2018

Login to get access

Abstract

Objectives

To assess the effects of growth hormone (GH) on lipid profiles in children and whether the effect is pharmacological.

Methods

The authors determined serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and low-density lipoprotein cholesterol (LDL-C) every year during 3-y GH treatment in 48 GH deficient (GHD) short children and 22 children with short stature born small for gestational age (SGA).

Results

The abnormally high levels of TC, non-HDL-C, and LDL-C showed a high frequency in GHD short children compared with epidemiological studies in Japan. The high prevalence of high level of TC was also shown in SGA short children. Three-year GH treatment decreased serum TC, non-HDL-C, and LDL-C levels in both patient groups.

Conclusions

GH treatment is clearly a pharmacological therapy in SGA short children and so may also be in GHD short children at the Japanese standard therapeutic dose. Taken together, GH improves lipid profiles, and its effect has the possibility of medical properties.
Literature
1.
Itoh E, Hizuka N, Fukuda I, Takano K. Metabolic disorders in adult growth hormone deficiency; a study of 110 patients at a single institute in Japan. Endocr J. 2006;53:539–45.CrossRefPubMed
2.
Claessen KM, Appleman-Dijkstra NM, Adoptie DMMM, et al. Metabolic profile in growth horomone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab. 2013;98:352–61.CrossRefPubMed
3.
Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH-an update. J Clin Endocrinol Metab. 2014;99:18–29.CrossRefPubMed
4.
Fukuda I, Hizuka N, Muraoka T, Ichihara A. Adult growth hormone deficiency: current concepts. Neurol Med Chir (Tokyo). 2014;54:599–605.CrossRef
5.
Uzunova I, Kirilov G, Zacharieva S, Shinkov A, Borissova A-M, Klinov K. Individual risk factors of the metabolic syndrome in adult patients with growth hormone deficiency-a cross-sectional case-control study. Exp Clin Endocrinol Diabetes. 2015;123:39–43.PubMed
6.
Chihara K, Koledova E, Shimatus A, et al. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency. Eur J Endocrinol. 2005;153:57–65.
7.
Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab. 2001;86:1061–5.CrossRefPubMed
8.
van der Sluis IM, Boot AM, Hop WC, de Rijke YB, Krenning EP, de Muinck K-SSMPF. Long-term effects of growthhormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficeient children: a 9-year follow-up study. Horm Res. 2002;58:207–14.PubMed
9.
Salerno M, Esposito V, Spinelli L, et al. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clin Endocrinol. 2004;60:630–6.CrossRef
10.
Ciresi A, Amatto MC, Criscimanna A, et al. Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol. 2007;156:353–60.CrossRefPubMed
11.
Meazza C, Elsedfy HH, Pagani S, Bozzola E, El Kholy M, Bozzola M. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res. 2014;46:219–23.PubMed
12.
Foster C, Burton A, Scholl J, Scott ML, Gunter V, McCormick K. Lipid patterns in treated growth hormone deficient children vs. short stature controls. J Pediatr Endocri Met. 2014;27:909–14.
13.
Kuromaru R, Kohno H, Ueyama N, Hassan HMS, Honda S, Hara T. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabokic effects. J Clin Endocrinol Metab. 1998;83:3890–6.PubMed
14.
Tenhola S, Martikainen A, Rahiala E, Herrgård E, Halonen P, Voutilainen R. Serum lipid concentrations and growth characteristics in 12-year-old children born small for gestational age. Pediatr Res. 2000;48:623–8.CrossRefPubMed
15.
Ogden C, Schoendorf KC, Kiely JL, Gillman MW. Fetal growth and childhood cholesterol levels in the United States. Pediatr Perinat Epidemiol. 2008;22:5–11.CrossRef
16.
Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab. 2000;85:3786–92.PubMed
17.
van Dijk M, Bannink EMN, van Pareren YK, Muldre PGH, Hokken-Koelega ACS. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab. 2007;92:160–5.CrossRefPubMed
18.
Kappelgaard AM, Kiyomi F, Horikawa R, Yokoya S, Tanaka T. The impact of long-term growth hormone treatment on metabolic parameters in Japanese patients with short stature born small for gestational age. Horm Res Paediatr. 2014;81:272–9.CrossRefPubMed
19.
Tanaka T, Yokoya S, Seino Y, et al. Long-term efficacy and safety of two doses of growth hormone in short Japanese children born small for gestational age. Horm Res Paediatr. 2011;76:411–8.CrossRefPubMed
20.
Tanaka T, Tachibana K, Shimatsu A, et al. A nationwide attempt to standardize growth hormone assays. Horm Res. 2005;64:6–11.PubMed
21.
Approved Guideline - Evaluation of precision performance of clinical chemistry devices, EP5-A. 1999. National Committee for Clinical Laboratory Standards
22.
Müller A, Scholz M, Blankenstein O, et al. Harmonization of growth hormone measurements with different immunoassays by data adjustment. Clin Chem Lab Med. 2011;49:1135–42.CrossRefPubMed
23.
Katsumata N, Shimatsu A, Tachibana K, et al. Continuing efforts to standardize measured serum growth hormone values in Japan. Endocr J. 2016;63:933–6.CrossRefPubMed
24.
Kubo T, Takahashi K, Furujo M, et al. Usefulness of non-fasting lipid parameters in children. J Pediatr Endocrinol Met. 2017;30:77–83.
25.
Asayama K, Ozeki T, Sugihara S, et al. Criteria for medical intervention in obese children: a new definition of ‘obesity disease’ in Japanese children. Pediatric Int. 2003;45:642–6.CrossRef
26.
Okada T, Murata M, Yamaguchi K, Harada K. New criteria of normal serum lipid levels in Japanese children: the nationwide study. Pediatr Int. 2002;44:596–601.CrossRefPubMed
27.
Abe Y, Okada T, Sugiura R, Yamauchi K, Murata M. Reference ranges for the non-high-density lipoprotein cholesterol levels in Japanese children and adolescents. J Atheroscler Thromb. 2015;22:669–75.CrossRefPubMed
28.
Lind S, Rudling M, Ericsson S, Olivecrona H, et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol. 2004;24:349–56.CrossRefPubMed
29.
Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP. Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activates in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis. 2000;153:491–8.CrossRefPubMed
30.
Tell GS, Mittelmark MB, Vellar OD. Cholesterol, high density lipoprotein cholesterol and triglycerides during puberty: the Oslo Youth study. Am J Epidemiol. 1985;122:750–61.CrossRefPubMed
31.
Finkelstein JW, Roffwarg HP, Boyard RM, Kream J, Hellman L. Age-related changes in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab. 1972;35:665–70.
32.
Martha PM Jr, Gorman KM, Blizzard RM, Rogol AD, Veldhuis JD. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab. 1992;74:336–44.PubMed
Metadata
Title
Effects of Growth Hormone Treatment on Lipid Profiles
Authors
Toshihide Kubo
Mahoko Furujo
Kyohei Takahashi
Yuki Hyodo
Hiroki Tsuchiya
Mariko Hattori
Shoko Fujinaga
Kenji Urayama
Publication date
01-04-2018
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 4/2018
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-017-2509-8

Other articles of this Issue 4/2018

Indian Journal of Pediatrics 4/2018 Go to the issue

Scientific Letter

Acute Pancreatitis in Dengue Fever

Editorial

Environmental Health of Children: Time to Translate Knowledge into Action

Scientific Letter

Congenital Self Healing Langerhans Cell Histiocytosis

Clinical Brief

Prevalence of Hypocalcemia in Seizures in Infancy

Review Article

Air Pollution and Allergic Airway Diseases: Social Determinantsand Sustainability in the Control and Prevention

Scientific Letter

Proprotein Convertase 1/3 Deficiency